Category Specific RSS

Opinion

Research Note: Speculative Buy on Crowd Media (ASX: CM8)

The Advisors at Emerald Financial recently released a Speculative Buy report on Crowd Media (ASX: CM8).

The Company has benefited from the growth in online-specific retail, something that has thrived through the COVID-19 pandemic due to isolation restrictions. Just look at a few of the more well-known ASX-listed retail companies that sell solely online have thrived due to this change in attitudes;

Kogan.com (ASX:KGN) went from $4 to $15 – 275% gain
Temple & Webster (ASX: TPW) went from $1.55 to $6.20 – 300% gain

Why will this likely continue? People value ease-of-use, cost, convenience, and variety. Something brick-and-mortar retailers simply can’t match.

Crowd Media have a unique strategy that allows them to combine this growth areas with another – influencer marketingAn area no other ASX-listed company specialises in.

Key highlights in the report include:

  • Personnel appointments with extensive commercial success in influencer marketing, inc Steven Schapera, Founder of BECCA Cosmetics;
  • Extensive network of 10,000+ social influencers & localised millennial knowledge of individual operating markets;
  • Four high-margin brand partnerships secured in first 9 months of business transformation;
  • Financial turnaround from $4.7m loss to positive underlying EBITDA for H2FY20;
  • A.I chatbot development to potentially revolutionise global influencer industry;
  • Takeover Target: Low to Medium

This is only a brief excerpt of the report. To download it in full, simply register for free below.

*Owners of this website are CM8 shareholders

**CM8 has engaged Principal IR on retainer to assist with Investor Communications

Alfred Chan is a Director of Principal Investor Relations (Principal) (ABN: 51 633 750 928) and an Authorised Representative of Emerald Financial Group ABN 85 106 823 741 which holds Australian Financial Services License number 241041.

Any advice contained in this presentation is general advice and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only.

“Investing is about understanding your risk” and every time you invest in the share market there is a risk of loss. If you are thinking about acquiring a financial product, you should consult our Financial Services Guide (FSG) at www.emeraldfinancial.com.au and the relevant Product Disclosure Statement first.

Please note past performance is not a reliable indicator of future performance.

All Figures in this report were correct as of 29th June 2020.

Alfred Chan

Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.

Recent Posts

AML3D announces stronger FY26, with positive EBITDA reported in the second half

Adelaide-based metal printing group books record $12.5 million revenue and a record $78 million sales…

2 days ago

Refurbished tech gives Harris Technology a second life

Harris Technology has found a higher-margin growth engine in an unlikely place: the market for…

4 days ago

Imagion Biosystems Advances MagSense® Phase 2 Trial

Imagion Biosystems (ASX: IBX) is moving its MagSense® HER2 Imaging Agent Phase 1b/2 clinical trial…

1 week ago

Acrux-developed Menopause Hormone Therapy to enter Australian market

Acrux (ASX:ACR) is set to bring its transdermal Estradiol spray Lenzetto® to the Australian market…

3 months ago

Evion Expands Critical Minerals Push with Nevada Fluorspar Option

The race to secure Western-aligned critical minerals supply chains is accelerating as governments and industry…

4 months ago

Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone

Green360 Technologies (ASX:GT3) has taken a major step forward in the commercialisation of its low-carbon…

4 months ago